IDBiologics
- Biotech or pharma, therapeutic R&D
IDBiologics is developing human monoclonal antibodies as infectious disease prophylaxis. The lead program is for BK Virus which affects nearly all kidney transplant patients in US and EU. BK infection, viremia and kidney damage result in patients from the use of immunosuppressive drugs. The #1 concern of transplant doctors is the management of BKV viremia. IVIG has been used for human proof of concept but is too expensive, unwieldy, and insufficiently potent. IDBio has an ultra-potent single antibody that can neutralize all 4 genotypes of BK virus, and a single dose can protect for more than six months. It's likely that a patient would receive 4 doses of BKV antibody starting with transplant.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}